Entellus Medical (NASDAQ:ENTL) will be releasing its earnings data after the market closes on Monday, February 19th. Analysts expect Entellus Medical to post earnings of ($0.44) per share for the quarter.
Entellus Medical (ENTL) opened at $24.00 on Monday. The firm has a market capitalization of $611.38, a PE ratio of -18.75 and a beta of -0.02. Entellus Medical has a fifty-two week low of $11.47 and a fifty-two week high of $25.58. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.
A number of research firms recently weighed in on ENTL. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. BidaskClub cut Entellus Medical from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. William Blair cut Entellus Medical from an “outperform” rating to a “market perform” rating in a report on Friday, December 8th. ValuEngine raised Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Finally, TheStreet raised Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $19.25.
In related news, Director Brian E. Farley sold 101,319 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $23.85, for a total value of $2,416,458.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Thomas P. Williamson sold 2,449 shares of the stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $24.08, for a total value of $58,971.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,942 shares of company stock valued at $2,599,658. Insiders own 7.70% of the company’s stock.
An institutional investor recently raised its position in Entellus Medical stock. State Street Corp increased its holdings in Entellus Medical Inc (NASDAQ:ENTL) by 26.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 140,856 shares of the medical technology company’s stock after acquiring an additional 29,386 shares during the period. State Street Corp owned approximately 0.56% of Entellus Medical worth $2,333,000 at the end of the most recent quarter. 74.02% of the stock is currently owned by institutional investors and hedge funds.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.